Delving into the Latest Updates on Oncoscience GmbH with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
神经系统疾病	1
肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

EGFR(表皮生长因子受体erbB1)	1

关联

1

项与 Oncoscience GmbH 相关的药物

Nimotuzumab

尼妥珠单抗

靶点

EGFR

作用机制

EGFR拮抗剂

在研机构

Oncoscience GmbH [+6]

原研机构

Center For Molecular Immunology

在研适应症

胰腺癌 [+17]

非在研适应症

腺癌 [+15]

最高研发阶段批准上市

首次获批国家/地区

印度

首次获批日期2006-09-11

100 项与 Oncoscience GmbH 相关的临床结果

登录后查看更多信息

0 项与 Oncoscience GmbH 相关的专利（医药）

登录后查看更多信息

1

项与 Oncoscience GmbH 相关的文献（医药）

2019-05-01·Journal of Neuro-Oncology2区 · 医学

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study

2区 · 医学

Article

作者: Reinhard, H ; Massimino, M ; Warmuth-Metz, M ; Graf, N ; Janssen, G ; Rutkowski, S ; Schlegel, P G ; Schmid, I ; Beilken, A ; Bach, F ; Iznaga-Escobar, N E ; Reuter, D ; Khuhlaeva, E ; Kramm, C ; Gorelishev, S K ; Biassoni, V ; Bode, U ; Fleischhack, G ; Kortmann, R-D

BACKGROUNDDiffuse intrinsic pontine glioma (DIPG) is a devastating cancer of childhood and adolescence.METHODSThe study included patients between 3 and 20 years with clinically and radiologically confirmed DIPG. Primary endpoint was 6-month progression-free survival (PFS) following administration of nimotuzumab in combination with external beam radiotherapy (RT). Nimotuzumab was administered intravenously at 150 mg/m² weekly for 12 weeks. Radiotherapy at total dose of 54 Gy was delivered between week 3 and week 9. Response was evaluated based on clinical features and MRI findings according to RECIST criteria at week 12. Thereafter, patients continued to receive nimotuzumab every alternate week until disease progression/unmanageable toxicity. Adverse events (AE) were evaluated according to Common Terminology Criteria for Adverse Events (CTC-AE) Version 3.0 (CTC-AE3).RESULTSAll 42 patients received at least one dose of nimotuzumab in outpatient settings. Two patients had partial response (4.8%), 27 had stable disease (64.3%), 10 had progressive disease (23.8%) and 3 patients (7.1%) could not be evaluated. The objective response rate (ORR) was 4.8%. Median PFS was 5.8 months and median overall survival (OS) was 9.4 months. Most common drug-related AEs were alopecia (14.3%), vomiting, headache and radiation skin injury (7.1% each). Therapy-related serious adverse events (SAEs) were intra-tumoral bleeding and acute respiratory failure, which were difficult to distinguish from effects of tumor progression.CONCLUSIONSConcomitant treatment with RT and nimotuzumab was feasible in an outpatient setting. The PFS and OS were comparable to results achieved with RT and intensive chemotherapy in hospitalized setting.

100 项与 Oncoscience GmbH 相关的药物交易

登录后查看更多信息

100 项与 Oncoscience GmbH 相关的转化医学

登录后查看更多信息